GH fragment
A fragment of growth hormone isolated for its fat-metabolism effects — which largely failed to reproduce in human trials.
AOD-9604 is a small piece of the human growth hormone molecule — the tail end, specifically — isolated on the theory that this fragment carries growth hormone's fat-breakdown activity without its effects on blood sugar or tissue growth. The theory was elegant. The human results were disappointing, and that is the most useful thing this page can tell you.
Growth hormone increases fat breakdown and inhibits fat formation. Researchers mapped which part of the molecule carried that effect and synthesized just that part, hoping to get the metabolic benefit without raising IGF-1 or affecting glucose. Mechanistically it does appear to work on fat cells in isolation. Whether that translates into meaningful fat loss in a living person is where the evidence stops supporting the story.
AOD-9604 corresponds to the C-terminal fragment (amino acids 177–191) of human growth hormone. It stimulates lipolysis and inhibits lipogenesis in adipose tissue, reportedly through beta-3 adrenergic receptor pathways, without binding the growth hormone receptor — hence no IGF-1 elevation and no effect on insulin sensitivity or glucose. Separate work has examined its effects on chondrocyte proliferation and cartilage regeneration.
Based on the human trial data, honestly: not much for fat loss. It is not that the compound does nothing in a dish, it is that the effect did not survive contact with a controlled human study.
Every page on this site includes this section. If a source only tells you what something does, you are reading marketing.
The safety profile from human trials is favorable — it was well tolerated, with no significant effects on glucose or IGF-1. In that narrow sense it is one of the safer compounds discussed here, which is faint praise for something that did not demonstrate efficacy. Not FDA-approved. Prohibited in sport under WADA rules. Not appropriate during pregnancy or breastfeeding.
Third-party testing with a batch-matched certificate of analysis, as always. Given the weak efficacy evidence, the more important question is whether you should be buying it at all rather than whose vial to buy.
The controlled human evidence does not support it. Animal studies were positive; a twelve-week randomized human trial in obese participants did not show significant benefit over placebo.
Yes, it is prohibited under WADA rules.
It is inexpensive, has a good safety profile, and the animal data makes for compelling marketing. That is not the same as it working.
General education only goes so far. If you want help deciding whether this is relevant to your goals, history, and current labs, schedule a consultation with the Bearing team.
Request a Consultation